LENZ Therapeutics (LENZ) Accounts Payables (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Accounts Payables of $10.9 million for Q1 2026, up 198.52% year-over-year from $3.7 million in Q1 2025, and up 162.28% quarter-over-quarter from $4.2 million in Q4 2025.
LENZ Therapeutics (LENZ) Accounts Payables (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Accounts Payables for 7 consecutive years, with $10.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 198.52% year-over-year to $10.9 million; the TTM figure through Mar 2026 stood at $10.9 million (up 198.52% YoY), while the FY2025 annual figure was $4.2 million, down 2.11% from the prior year.
- Accounts Payables advanced to $10.9 million in Q1 2026 per LENZ's latest filing, from $4.2 million in the prior quarter.
- Across five years, Accounts Payables topped out at $10.9 million in Q1 2026 and bottomed at $2.0 million in Q1 2023.
- Historically, Accounts Payables has averaged $4.2 million across 5 years, with a median of $3.8 million in 2023.
- Annual changes were most pronounced in 2024 — Accounts Payables jumped 257.98% — and 2025, when it sank 48.66%.
- LENZ Therapeutics' Accounts Payables stood at $2.6 million in 2022, then jumped by 118.98% to $5.7 million in 2023, then slipped by 25.46% to $4.3 million in 2024, then decreased by 2.11% to $4.2 million in 2025, then soared by 162.28% to $10.9 million in 2026.
- Business Quant data shows LENZ's Accounts Payables at $10.9 million in Q1 2026, $4.2 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | 6.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.65 Mn |
| Mar 31, 2026 | 10.93 Mn |
| Dec 31, 2025 | 4.17 Mn |
| Sep 30, 2025 | 4.32 Mn |
| Jun 30, 2025 | 2.85 Mn |
| Mar 31, 2025 | 3.66 Mn |
| Dec 31, 2024 | 4.26 Mn |
| Sep 30, 2024 | 2.76 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Mar 31, 2024 | 7.13 Mn |
| Dec 31, 2023 | 5.71 Mn |
| Sep 30, 2023 | 3.75 Mn |
| Jun 30, 2023 | 2.72 Mn |
| Mar 31, 2023 | 1.99 Mn |
| Dec 31, 2022 | 2.61 Mn |
| Sep 30, 2022 | 3.97 Mn |
| Jun 30, 2022 | 3.62 Mn |
| Mar 31, 2022 | 3.07 Mn |
| Dec 31, 2021 | 2.45 Mn |
| Sep 30, 2021 | 1.76 Mn |